 David Higgins
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 68 | 2.320 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 397 | 1.190 |
Why?
| | Rural Health Services | 1 | 2024 | 137 | 0.790 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 42 | 0.790 |
Why?
| | Gonorrhea | 1 | 2023 | 61 | 0.760 |
Why?
| | Sexual Health | 1 | 2023 | 59 | 0.760 |
Why?
| | Chlamydia Infections | 1 | 2023 | 78 | 0.750 |
Why?
| | Physicians, Primary Care | 1 | 2024 | 223 | 0.720 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 163 | 0.700 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 227 | 0.680 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 502 | 0.640 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 229 | 0.610 |
Why?
| | Mitral Valve Insufficiency | 3 | 2024 | 71 | 0.610 |
Why?
| | HIV Infections | 2 | 2023 | 2945 | 0.570 |
Why?
| | Vaccines | 1 | 2023 | 402 | 0.570 |
Why?
| | Vaccination | 5 | 2024 | 1438 | 0.560 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 59 | 0.510 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1159 | 0.500 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 836 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1321 | 0.470 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 315 | 0.460 |
Why?
| | Telemedicine | 1 | 2023 | 876 | 0.440 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 334 | 0.430 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 141 | 0.420 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 23 | 0.410 |
Why?
| | Heart Ventricles | 1 | 2017 | 745 | 0.380 |
Why?
| | Interleukin-10 | 3 | 2014 | 304 | 0.360 |
Why?
| | Stroke Volume | 3 | 2024 | 584 | 0.320 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 188 | 0.320 |
Why?
| | Cross Infection | 1 | 2012 | 249 | 0.310 |
Why?
| | Implants, Experimental | 1 | 2009 | 21 | 0.310 |
Why?
| | Mitral Valve | 3 | 2024 | 96 | 0.310 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 32 | 0.300 |
Why?
| | Tuberculosis | 3 | 2010 | 280 | 0.290 |
Why?
| | Vitamin D | 1 | 2012 | 399 | 0.290 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 20 | 0.290 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 150 | 0.270 |
Why?
| | Length of Stay | 1 | 2012 | 1237 | 0.250 |
Why?
| | Pregnancy | 3 | 2023 | 6870 | 0.250 |
Why?
| | Female | 16 | 2024 | 74016 | 0.240 |
Why?
| | Intensive Care Units | 1 | 2012 | 871 | 0.240 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2024 | 197 | 0.240 |
Why?
| | Critical Illness | 1 | 2012 | 836 | 0.240 |
Why?
| | Humans | 20 | 2024 | 138972 | 0.230 |
Why?
| | Biocompatible Materials | 1 | 2009 | 426 | 0.230 |
Why?
| | Mass Screening | 2 | 2023 | 1296 | 0.230 |
Why?
| | Ventricular Function, Right | 2 | 2024 | 278 | 0.220 |
Why?
| | Pandemics | 2 | 2023 | 1645 | 0.220 |
Why?
| | Heart Failure | 1 | 2017 | 2065 | 0.220 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 68 | 0.210 |
Why?
| | Hepatitis B virus | 1 | 2023 | 34 | 0.200 |
Why?
| | Sepsis | 2 | 2022 | 611 | 0.190 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 50 | 0.180 |
Why?
| | Homosexuality, Male | 1 | 2023 | 193 | 0.180 |
Why?
| | HIV | 1 | 2023 | 246 | 0.180 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2030 | 0.180 |
Why?
| | Ventricular Remodeling | 1 | 2024 | 257 | 0.180 |
Why?
| | Infant, Newborn | 2 | 2023 | 6158 | 0.180 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 185 | 0.170 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 147 | 0.170 |
Why?
| | Exercise Test | 1 | 2024 | 621 | 0.170 |
Why?
| | Child | 6 | 2024 | 21936 | 0.170 |
Why?
| | Disease Progression | 3 | 2017 | 2752 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1543 | 0.160 |
Why?
| | Retrospective Studies | 4 | 2023 | 15901 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 980 | 0.160 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 17 | 0.160 |
Why?
| | Infant | 2 | 2024 | 9577 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2024 | 536 | 0.150 |
Why?
| | Echocardiography | 2 | 2024 | 638 | 0.150 |
Why?
| | Chemokines, C | 2 | 2008 | 5 | 0.140 |
Why?
| | Genomics | 1 | 2023 | 797 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 699 | 0.140 |
Why?
| | Deglutition Disorders | 2 | 2013 | 148 | 0.140 |
Why?
| | Ferritins | 1 | 2017 | 67 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 626 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2023 | 733 | 0.130 |
Why?
| | Male | 10 | 2024 | 68250 | 0.130 |
Why?
| | United States | 2 | 2024 | 15074 | 0.120 |
Why?
| | Adult | 6 | 2024 | 38393 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 488 | 0.120 |
Why?
| | Lung | 5 | 2013 | 4103 | 0.120 |
Why?
| | Tracheostomy | 1 | 1997 | 133 | 0.120 |
Why?
| | Iron | 1 | 2017 | 324 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1377 | 0.110 |
Why?
| | Parents | 1 | 2023 | 1423 | 0.110 |
Why?
| | Colorado | 1 | 2024 | 4543 | 0.110 |
Why?
| | Cytokines | 4 | 2010 | 2083 | 0.110 |
Why?
| | Th1 Cells | 3 | 2010 | 140 | 0.110 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 22 | 0.100 |
Why?
| | Primary Health Care | 1 | 2024 | 1776 | 0.100 |
Why?
| | Mice | 9 | 2014 | 17828 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 45 | 0.100 |
Why?
| | Sialorrhea | 1 | 2013 | 1 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1267 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2010 | 787 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 109 | 0.090 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 39 | 0.090 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 50 | 0.090 |
Why?
| | Biomarkers | 2 | 2017 | 4095 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 228 | 0.090 |
Why?
| | Middle Aged | 4 | 2024 | 33782 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5884 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 335 | 0.090 |
Why?
| | Critical Care | 1 | 1997 | 653 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1097 | 0.090 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 396 | 0.090 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1148 | 0.080 |
Why?
| | Prospective Studies | 3 | 2024 | 7661 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 2962 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5152 | 0.080 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 399 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 202 | 0.080 |
Why?
| | Animals | 11 | 2014 | 37243 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 165 | 0.080 |
Why?
| | Cause of Death | 1 | 2012 | 433 | 0.080 |
Why?
| | Child, Preschool | 1 | 2024 | 11158 | 0.080 |
Why?
| | Hemorrhage | 1 | 2014 | 747 | 0.080 |
Why?
| | Risk Factors | 1 | 2023 | 10385 | 0.070 |
Why?
| | Prognosis | 1 | 2017 | 3995 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 88 | 0.070 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 326 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1281 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2687 | 0.070 |
Why?
| | Oximetry | 1 | 2009 | 118 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 51 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1730 | 0.070 |
Why?
| | Chronic Disease | 3 | 2010 | 1804 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2009 | 1192 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 325 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 573 | 0.070 |
Why?
| | Granuloma | 1 | 2007 | 97 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 174 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 366 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 366 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5801 | 0.060 |
Why?
| | Observer Variation | 2 | 2024 | 350 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3313 | 0.060 |
Why?
| | Patient Discharge | 1 | 2012 | 915 | 0.060 |
Why?
| | Aged | 4 | 2024 | 24172 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2010 | 3029 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 539 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2745 | 0.060 |
Why?
| | Adolescent | 1 | 2024 | 21581 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2008 | 491 | 0.050 |
Why?
| | Pneumonia | 1 | 2010 | 644 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2024 | 90 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 4182 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1939 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 651 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 15 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 910 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2013 | 10921 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 421 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 3143 | 0.040 |
Why?
| | Transcriptome | 1 | 2022 | 966 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1746 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 280 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 8 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 411 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 88 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2014 | 127 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1482 | 0.020 |
Why?
| | Movement Disorders | 1 | 2013 | 64 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 77 | 0.020 |
Why?
| | Injections | 1 | 2013 | 190 | 0.020 |
Why?
| | Patient Care Team | 1 | 1997 | 647 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 143 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 3636 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4316 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 769 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 37 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 26 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 214 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 140 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 309 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1934 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 689 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 240 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 330 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 196 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2497 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 181 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 595 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2050 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5591 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 977 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2228 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5744 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 144 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1985 | 0.010 |
Why?
| | Swine | 1 | 2001 | 800 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|